Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 5
2005 13
2007 7
2008 1
2009 4
2010 9
2011 3
2012 12
2013 15
2014 24
2015 17
2016 14
2017 8
2018 8
2019 10
2020 5
2021 9
2022 12
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: madhusudan s. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Valle J, et al. Among authors: madhusudan s. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721. N Engl J Med. 2010. PMID: 20375404 Free article. Clinical Trial.
Towards Personalized Management of Ovarian Cancer.
Algethami M, Kulkarni S, Sadiq MT, Tang HKC, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Algethami M, et al. Among authors: madhusudan s. Cancer Manag Res. 2022 Dec 15;14:3469-3483. doi: 10.2147/CMAR.S366681. eCollection 2022. Cancer Manag Res. 2022. PMID: 36545222 Free PMC article. Review.
Targeting DNA damage repair precision medicine strategies in cancer.
Brownlie J, Kulkarni S, Algethami M, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Brownlie J, et al. Among authors: madhusudan s. Curr Opin Pharmacol. 2023 Jun;70:102381. doi: 10.1016/j.coph.2023.102381. Epub 2023 May 4. Curr Opin Pharmacol. 2023. PMID: 37148685 Free article. Review.
Intraperitoneal gene therapy.
Madhusudan S, Ganesan TS. Madhusudan S, et al. Cancer Treat Res. 2007;134:515-24. doi: 10.1007/978-0-387-48993-3_35. Cancer Treat Res. 2007. PMID: 17633078 Review. No abstract available.
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M, Persson JL, Gudas LJ, Rakha E, Robinson BD, Khani F, Martin LM, Moyer JE, Brownlie J, Madhusudan S, Allegrucci C, James VH, Rutland CS, Fray RG, Ntekim A, de Brot S, Mongan NP, Jeyapalan JN. Harris AE, et al. Among authors: madhusudan s. Front Endocrinol (Lausanne). 2022 Oct 3;13:1006101. doi: 10.3389/fendo.2022.1006101. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36263323 Free PMC article. Review.
Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.
Ali R, Aouida M, Alhaj Sulaiman A, Madhusudan S, Ramotar D. Ali R, et al. Among authors: madhusudan s. Int J Mol Sci. 2022 Jun 29;23(13):7241. doi: 10.3390/ijms23137241. Int J Mol Sci. 2022. PMID: 35806243 Free PMC article. Review.
173 results